Skip to main content
main-content

17-06-2021 | ASCO 2021 | Conference coverage | Video

INDUCE-1 points to ICOS agonist activity in advanced urothelial cancer

Arjun Balar talks through the INDUCE-1 trial findings for patients with advanced urothelial carcinoma who were given the ICOS agonist feladilimab alone or alongside pembrolizuamb (6:39).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

ESMO Congress 2021

Access our ongoing coverage including the latest news and expert video interviews.

Image Credits